BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11502003)

  • 1. High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene.
    Hillig RC; Coulie PG; Stroobant V; Saenger W; Ziegler A; Hülsmeyer M
    J Mol Biol; 2001 Jul; 310(5):1167-76. PubMed ID: 11502003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
    Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
    Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
    Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
    Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
    Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
    Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry.
    Zhou M; Peng JR; Zhang HG; Wang HX; Zhong ZH; Pan XY; Chen WF; Leng XS
    Immunol Lett; 2005 Jun; 99(1):113-21. PubMed ID: 15885805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomic structure of a human MHC molecule presenting an influenza virus peptide.
    Silver ML; Guo HC; Strominger JL; Wiley DC
    Nature; 1992 Nov; 360(6402):367-9. PubMed ID: 1448154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
    Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
    J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
    Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4.
    Jia ZC; Ni B; Huang ZM; Tian Y; Tang J; Wang JX; Fu XL; Wu YZ
    Clin Dev Immunol; 2010; 2010():567594. PubMed ID: 21350607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
    Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
    J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
    Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
    Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
    Duffour MT; Chaux P; Lurquin C; Cornelis G; Boon T; van der Bruggen P
    Eur J Immunol; 1999 Oct; 29(10):3329-37. PubMed ID: 10540345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
    Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexpression of MAGE-A peptides and HLA class I molecules in hepatocellular carcinoma.
    Roch N; Kutup A; Vashist Y; Yekebas E; Kalinin V; Izbicki JR
    Anticancer Res; 2010 May; 30(5):1617-23. PubMed ID: 20592351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
    Douat-Casassus C; Marchand-Geneste N; Diez E; Gervois N; Jotereau F; Quideau S
    J Med Chem; 2007 Apr; 50(7):1598-609. PubMed ID: 17328535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
    Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
    J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.